I trained at University College London where I gained a first class degree and carried out my surgical training in the University of Leeds. I set up a clinical research project for my higher degree in Leeds and then moved to the Univeristy of Newcastle upon Tyne to train in Urological Surgery as a Clinical Lecturer, where I also worked with Professor Adrian Harris. I became Senior Lecturer and subsequently was appointed to the Chair of Surgery and Head of School, and then took up the position of Director of Research at the Medical School. In 2002 I was appointed to the Foundation Chair of Surgical Oncology at the University of Cambridge where I was a Senior Group Leader in the CRUK funded Cambridge Institute carrying out translational research into prostate cancer.
I have published over 490 peer-reviewed papers and my publications have an “H” index of >65 and have been cited over 14,500 times with an average 650 times per year. I have over 40 papers cited more than 100 times. Nine people I have trained have been appointed to Chairs of Urology or Surgery.
- British Association of Urological Surgeons
- Royal College of Surgeons of England and Edinburgh
- Academy of Medical Sciences
- Royal Society of Biology
- Faculty of Pharmaceutical Medicine at the Royal College of Physicians
- European Association of Urologists
- American Urological Association
- Corresponding Member of the American Association of Genito-Urinary Surgeons (1999 - present)
- Urological Society of Australasia
CBE, FMedSci FRCS
Professor of Surgical Oncology
I joined Oxford in August 2015 as Professor of Surgical Oncology.
At the Cancer Research UK Cambridge Institute, my research focused on the molecular pathology of prostate cancer, particularly on how the androgen receptor interacts with the prostate cancer genome in order to identify potential biological targets and to stratify risk. I also am one of the Principal Investigators on the CRUK funded prostate cancer component of the International Cancer Genome Consortium (ICGC). This latter research is uncovering novel insights about the development of prostate cancer and how it metastases.
From 2002 to 2014, I worked at the Cambridge University Hospitals NHS Trust where I re-developed the clinical department and ensured its position as the Regional Uro-Oncology Centre. In 2005, I introduced robotic prostatectomy and led the regional service for retro-peritoneal node dissections for testis cancer.
The da Vinci surgical robot has revolutionised prostate surgery enabling surgeons to carry out minimally invasive surgery with greater precision. The method reduces blood loss and other complications associated with traditional open surgery, allowing men to go home sooner. Over 1,500 men have been treated at the Cambridge Centre with excellent published outcomes.
I am excited about the prospects of continuing the translational work that I have been doing on prostate cancer, particularly using the large bio-repository from ProtecT and ProMPT. Collaboration with colleagues here in Oxford will add real value to the links we already have established to better study this disease.
In 2014, I also moved to a brand new global role in Elsevier as their Senior Vice President of Research where I am helping them develop new informatics solutions for researchers.
- CBE for services to surgery in The Queen's 2014 New Year's Honours List
- Member of the King's Fund Management Committee (1996 - 2002) and the General Council (2002 - present)
- Victor Horsley (2009), Moynihan (2010) and Zachary Cope Lecturer (2011)
- Senior Investigator of the NIHR (2008)
- Elected to the Council of the Royal College of Surgeons of England (2002 – 2008)
- Elected to Council of Academy of Medical Sciences (2006)
- St Peter's Medal, BAUS, 2001
- Chairman of the SAC in Urology, 1998 – 2001
- Founding Fellow, The Academy of Medical Sciences, 1998
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.
Neal DE. et al, (1985), Lancet, 1, 366 - 368
The epidermal growth factor receptor and the prognosis of bladder cancer.
Neal DE. et al, (1990), Cancer, 65, 1619 - 1625
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer.
Sigalas I. et al, (1996), Nat Med, 2, 912 - 917
Outcome of elective prostatectomy.
Neal DE. et al, (1989), BMJ, 299, 762 - 767
CD133, a novel marker for human prostatic epithelial stem cells.
Richardson GD. et al, (2004), J Cell Sci, 117, 3539 - 3545
Tip60 is a nuclear hormone receptor coactivator.
Brady ME. et al, (1999), J Biol Chem, 274, 17599 - 17604
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor.
Massie CE. et al, (2007), EMBO Rep, 8, 871 - 878
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.
Asim M. et al, (2017), Nat Commun, 8
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
Johnston TJ. et al, (2017), Eur Urol, 71, 381 - 388
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
Donovan JL. et al, (2016), N Engl J Med, 375, 1425 - 1437
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
Hamdy FC. et al, (2016), N Engl J Med, 375, 1415 - 1424
Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes.
Simpkin AJ. et al, (2016), Stat Methods Med Res, 25, 1875 - 1891